SCHEMBL2963749

SCHEMBL2963749

OC1CCN(c2ccc(Cl)nn2)CC1

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.67
HTT P42858 1/20 0.67
CYP1A2 P05177 1/20 0.62
KMT2A Q03164 2/20 0.60
MEN1 O00255 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
BPTF Q12830 1/20 0.59
CHRNB2 P17787 3/20 0.54
CHRNA4 P43681 3/20 0.54
CHRNB4 P30926 2/20 0.54
CHRNA3 P32297 2/20 0.54
PANK3 Q9H999 2/20 0.48
ALDH1A1 P00352 1/20 0.47
LCAT P04180 1/20 0.44
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethane SCHEMBL27265380 0.97 LMNA (0.63) LMNAHTTCYP1A2KMT2AMEN1
Propane SCHEMBL10588661 0.94 LMNA (0.60) LMNAHTTCYP1A2KMT2AMEN1
SCHEMBL1977615 0.90 LMNA (0.59) LMNAHTTCYP1A2KMT2AMEN1
SCHEMBL1977612 0.90 LMNA (0.59) LMNAHTTCYP1A2KMT2AMEN1
SCHEMBL11908486 0.82 CYP1A2 (0.62) LMNAHTTCYP1A2KMT2AMEN1
SCHEMBL2009311 0.82 CYP1A2 (0.62) LMNAHTTCYP1A2KMT2AMEN1
SCHEMBL3595416 0.81 CHRNB2 (0.62) LMNAHTTCYP1A2KMT2AMEN1
SCHEMBL9198277 0.81 LMNA (0.61) LMNAHTTCYP1A2KMT2AMEN1
SCHEMBL1977246 0.80 LMNA (1.00) LMNAHTTCYP1A2KMT2AMEN1
SCHEMBL31200769 0.80 CYP1A2 (0.60) LMNAHTTCYP1A2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023093728-A1 BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF 江苏先声药业有限公司 2023-06-01 WO disclosed
WO-2023093728-A1 BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF 江苏先声药业有限公司 2023-06-01 WO disclosed
US-11013724-B2 Glutaminase inhibitors University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2021-05-25 US disclosed
US-11013724-B2 Glutaminase inhibitors University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2021-05-25 US disclosed
US-20190167648-A1 GLUTAMINASE INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2019-06-06 US disclosed
US-20190167648-A1 GLUTAMINASE INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2019-06-06 US disclosed
US-10245254-B2 Glutaminase inhibitors University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2019-04-02 US disclosed
US-10245254-B2 Glutaminase inhibitors University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2019-04-02 US disclosed
US-20170290815-A1 GLUTAMINASE INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2017-10-12 US disclosed
US-20170290815-A1 GLUTAMINASE INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2017-10-12 US disclosed
US-20100004245-A1 AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2010-01-07 US disclosed
US-20100004245-A1 AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2010-01-07 US disclosed
US-20100004245-A1 AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2010-01-07 US disclosed
EP-2076509-A1 AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE Merck Frosst Canada Ltd. (CA) 2009-07-08 EP disclosed
CN-101389630-A Protein kinase inhibitors ABBOTT LAB (US) 2009-03-18 CN disclosed
EP-1973917-A2 PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2008-10-01 EP disclosed
WO-2008046226-A1 AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2008-04-24 WO disclosed
WO-2008046226-A1 AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2008-04-24 WO disclosed
US-20070203143-A1 PROTEIN KINASE INHIBITORS ABBVIE INC. 2007-08-30 US disclosed
WO-2007079164-A2 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170290815-A1 GLUTAMINASE INHIBITORS GLUL, ASNS, GLS LMNA 2248/4885HTT 1247/4885CYP1A2 515/4885
US-10245254-B2 Glutaminase inhibitors GLUL, ASNS, GLS LMNA 2248/4885HTT 1247/4885CYP1A2 515/4885
US-20190167648-A1 GLUTAMINASE INHIBITORS GLUL, ASNS, GLS LMNA 2330/4885HTT 1309/4885CYP1A2 563/4885
US-11013724-B2 Glutaminase inhibitors GLUL, ASNS, GLS LMNA 2330/4885HTT 1309/4885CYP1A2 563/4885
US-20100004245-A1 AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE SCD, SCD5, SREBF1 LMNA 898/4885HTT 3364/4885CYP1A2 478/4885
US-20070203143-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 LMNA 1953/4885HTT 2695/4885CYP1A2 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.